MedTrace Logo

Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®

NCT03255980 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-12-16

Study results available
· View outcomes & findings →

Summary

To evaluate the performance of Xonrid® in the prevention and treatment of G2 radiation dermatitis in breast and head \& neck cancer patients.

Conditions

  • Radiodermatitis
  • Quality of Life

Interventions

DEVICE

Xonrid® gel

Water based gel for the management of toxicity skin symptoms induced by Radiotherapy

OTHER

Standard of Care

Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines

Sponsors & Collaborators

  • Helsinn Healthcare SA

    lead INDUSTRY

Principal Investigators

  • Orlandi Ester, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-15
Primary Completion
2019-02-20
Completion
2020-01-22

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03255980 on ClinicalTrials.gov